0 Items  |   £0.00
T: +44 (0)1562 825286       E: info@SevernBiotech.com
about us
To order or for other enquiries:
Email: info@severnbiotech.com
Tel: +44(0)1562-825286
Fax: +44(0)1562-825284

To search this catalogue press Ctrl+F and enter the required information.
Alternatively click below.
Category List
Index
Glossary
Guidance Notes


Catalogue Peptides - Contents




Adrenocorticotrophic Hormone (ACTH) and Related Peptides

SBP0001 - ACTH (1-39), human
Corticotropin
MW: 4541.7
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH
Review: "ACTH and Related Peptides: Structure, Regulation & Action" (1977) Ann. N.Y. Acad. Sci.
297, 1-641.
500µg
1mg


SBP0002 - ACTH (1-24), human
Tetracosactide
MW: 2933.9
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH
Jaquet, Y.F. (1978) Science 291, 1032.
1mg
5mg


SBP0003 - ACTH (1-39), porcine
MW: 4567.6
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH
500µg
1mg

SBP0004 - [D-Arg8]-ACTH (4-10)
MW: 962.2
H-Met-Glu-His-Phe-D-Arg-Trp-Gly-OH
This substituted ACTH (4-10) fragment has shown to be an effective MC4 antagonist.
Adan RA et al. (1996) Brain Res. Mol. Brain Res. 36, 37 - 44.
5mg
25mg

SBP0005 - [Pro8&10,Gly9]-ACTH (4-10)
MW: 814.1
H-Met-Glu-His-Phe-Pro-Gly-Pro-OH
5mg
25mg

SBP0006 - ACTH (5-10)
MW: 830.91
H-Glu-His-Phe-Arg-Trp-Gly-OH
10mg
25mg

SBP0007 - ACTH (34-39)
MW: 722.9
H-Ala-Phe-Pro-Leu-Glu-Phe-OH
10mg
25mg

AMPA Type Glutamate Receptor and Related Peptides

SBP0008 - Pep1-TGL
MW: 990.14
H-Ser-Ser-Gly-Met-Pro-Leu-Gly-Ala-Thr-Gly-Leu-OH
Peptide containing the 'TGL' motif that corresponds to the C terminus of the AMPA receptor GluR1 subunit.
Hayashi et al (2000) Science 287 2262
1mg
5mg

SBP0009 - Pep1-AGL
MW: 960.11
H-Ser-Ser-Gly-Met-Pro-Leu-Gly-Ala-Thr-Gly-Leu-OH
Analogue of Pep1-TGL, a peptide containing the 'TGL' motif that corresponds to the C terminus of the AMPA receptor GluR1 subunit.
Hayashi et al (2000) Science 287 2262
1mg
5mg

SBP0010 - Pep2-AVKI
MW: 1268.47
H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Ala-Val-Lys-Ile-OH
Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluR2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluR2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).
Li et al (1999) Nature.Neurosci. 2 972.
1mg

5mg

SBP0011 - Pep2-EVKI
MW: 1326.51
H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Glu-Val-Lys-Ile-OH
Inhibitor peptide that selectively disrupts binding of the aMPA receptor subunit GluR2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluR2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).
Li et al (1999) Nature.Neurosci. 2 972.
1mg
5mg

SBP0012 - Pep2-SVKI
MW: 1284.47
H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Ser-Val-Lys-Ile-OH
Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Disrupts binding of the GluR2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and protein interacting with C kinase (PICK1). Increases amplitude of AMPA receptor mediated currents and blocks long-term depression (LTD).
Li et al (1999) Nature.Neurosci. 2 972.
1mg
5mg

SBP0013 - Pep2-SVKE
MW: 1300.43
H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Ser-Val-Lys-Glu-OH
Inactive control peptide analogue of pep2-SVKI, an inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit.
Li et al (1999) Nature.Neurosci. 2 972.
1mg
5mg

SBP0014 - Pep2m
MW: 1173.44
H-Lys-Arg-Met-Lys-Val-Ala-Lys-Asn-Ala-Gln-OH
Peptide inhibitor of the interaction between the C-terminus of the GluR2 (AMPA receptor) subunit and the N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currentsin CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression.
Nishimune et al (1998) Neuron 21 87-97.
1mg
5mg

SBP0015 - Pep4c
MW: 1146.42
H-Lys-Arg-Met-Lys-Val-Ala-Lys-Ser-Ala-Gln-OH
Inactive control peptide analogue of pep2m, an inhibitor of the interaction between the C-terminus of the GluR2 (AMPA receptor) subunit and the N-ethylmaleimide-sensitive fusion protein (NSF),
Nishimune et al (1998) Neuron 21 87-97.
1mg
5mg

Amylin (Diabetes Associated Peptide Amide; DAP Amide) and Related Peptides

SBP0016 - Amylin, human
Diabetes-associated Peptide (DAP) Amide, human
MW: 3904.1
H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Cys2-7, cyclic)
Diabetes-associated peptide (DAP), the C-terminal deaminated form of amylin, was originally isolated from amyloid rich pancreatic tissue of diabetic patients. It also occurs in normal adult islet cells. Amylin inhibits basal and insulin stimulated glucose uptake. Both DAP and amylin are active in vivo and in vitro.
Cooper, G.J.S. et al. (1987) Proc. Soc. Natl. Acad. Sci. USA 84, 8628; Westermark, P. et al. (1987) Proc. Soc. Natl. Acad. Sci. 84, 3881.
500µg
1mg

SBP0017 - Amylin (8-37), human
MW: 3183.9
H-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2
Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116.
500µg
1mg

SBP0018 - N-Acetyl-Amylin (8-37), human
MW: 3225.9
Ac-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2
Very effective antagonist of amylin inhibition of glycogen accumulation.
Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116.
500µg
1mg

SBP0019 - Amylin, rat
Diabetes-associated Peptide (DAP) Amide, rat
MW: 3920.8
H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Cys2-7, cyclic)
Leffert, J.D. et al. (1989) Proc. Soc. Natl. Acad. Sci. 86, 3127
500µg
1mg

SBP0020 - Amylin (8-37), rat
MW: 3200.8
H-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2
Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116.
500µg
1mg

SBP0021 - N-Acetyl-Amylin (8-37), rat
MW: 3242.6
Ac-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2
Very effective antagonist of amylin action on glycogen accumulation.
Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116.
500µg
1mg

SBP0022 - proIAPP
MW: 7401.43
H-Thr-Pro-Ile-Glu-Ser-His-Gln-Val-Glu-Lys-Arg-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-Gly-Lys-Arg-Asn-Ala-Val-Glu-Val-Leu-Lys-Arg-Glu-Pro-Leu-Asn-Tyr-Leu-Pro-Leu-OH
This 67-mer is the pre-pro-protein for amylin, human.
500µg
1mg

Amyloid ß-Protein Fragments

SBP0023 - Amyloid ß-Protein (1-43)
MW: 4615.21
H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr-OH
The amyloid ß-protein consists of a 39-43 amino-acid polypeptide and is the primary constituent of senile plaques and cerebrovascular deposits in Alzheimer's disease and Down's Syndrome. Is additionally acts as an inhibitor of the Ubiquitin dependant protein degradation in vitro.
Kang, J. et al. (1987) Nature 325, 733; Goldgaber, D. et al. (1987) Science 235, 877; Murrell, J. et al. (1991) Science 254, 97; Pike, C.J. et al. (1994) Neuroscience 63, 517.
500µg
1mg

SBP0024 - Amyloid ß-Protein (1-42)
MW: 4514.1
H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
This 42-amino acid peptide is the predominant form of amyloid beta-protein in the brains of Alzheimer patients.
Kang, J. et al. (1987) Nature 325, 733; Goldgaber, D. et al. (1987) Science 235, 877; Murrell, J. et al.(1991) Science 254, 97; Pike, C.J. et al. (1994) Neuroscience 63, 517.
500µg
1mg

SBP0025 - Amyloid ß-Protein (1-40)
MW: 4329.8
H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH
This peptide has been demonstrated to possess both neurotrophic and neurotoxic activities.
Yankner et al. (1990) Science 250, 279; Maggio, J.E. et al. (1992) Proc. Soc. Natl. Acad. Sci. 89, 5462.
500µg
1mg

SBP0026 - Amyloid ß-Protein (25-35)
MW: 1060.6
H-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH
Fragment with neurotrophic and neurotoxic activities.
Yankner et al. (1990) Science 250, 279; Klegeris, A. et al. (1994) Biochem. Biophys. Res. Commun. 199, 984; Pike, C.J. et al. (1994) Neuroscience 63, 517; Pike, C.J. et al. (1995) J. Neurochem. 64, 253.
1mg
5mg

SBP0027 - Amyloid Precursor Protein ß-Secretase Inhibitor
MW: 1651.8
H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe-OH
This statin analogue of an amyloid precursor protein fragment is an effective inhibitor of ß-secretase from human brain. ß-secretase is responsible for proteolytic cleavage of N-terminal fragment from amyloid precursor protein between residues 671 and 672, leading to the generation of the soluble form of amyloid precursor protein. The C-terminal fragment is further processed by gamma-secretase to form the amyloid ß-peptide assumed to be the pathological component of Alzheimers's disease.
Sinha S. et al. (1999) Nature 402, 537.
1mg
5mg

Angiotensin and Related Peptides

SBP0028 - Angiotensin I, human (Decapeptide)
MW: 1296.7
H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH
The above sequence has been shown to be common to the human, horse, sheep, pig and rat species.
Felix, D. et al. (1991) Hypertension 6, 111.
25mg
100mg

SBP0029 - Angiotensin II, human (Octapeptide)
MW: 1046.3
H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
The above sequence has been shown to be common to the human, horse, sheep, pig and rat species.
Inagami, T. et al. (1988) Cardiovascular Drugs Therap. 2, 453.
25mg
100mg

SBP0030 - [Des-Leu10]-Angiotensin I
Angiotensin I (1-9)
MW: 1183.5
H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-OH
5mg
25mg

SBP0031 - [Sar1]-Angiotensin II
MW: 1002.3
H-Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
Hall, M.M. et al. (1973) J. Pharm. Exp. Ther. 188, 222; Mendelsohn, F.A.O. et al. (1984) Proc. Soc.
Natl. Acad. Sci. USA 81, 1575.
5mg
25mg

SBP0032 - [Asn1,Val5]-Angiotensin II
MW: 1031.5
NH2-Asn-Arg-Val-Tyr-Val-His-Pro-Phe-OH
The native form of angiotensin II in teleost fish
Olsen K.R. (1992) Fish Physiology XII . B. The Cardiovascular System, pp 136-232. Academic Press (Eds.: WS Hoar, DJ Randall, AP Farrell), Olsen K.R. et al. (1992) J. Exptl. Biol. 194, 117.
25mg
100mg

Atrial Natriuretic Peptide (ANP) and Related Peptides

SBP0033 - Atrial Natriuretic Peptide (1-28), human, porcine
ANF (1-28), human, porcine
MW: 3080.9
H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Cys7-23, cyclic)
Kangawa, K. et al. (1984) Biochem. Biophys. Res. Commun. 118, 131.
500µg
1mg

SBP0034 - Atrial Natriuretic Peptide (1-28), rat
ANF (1-28), rat
MW: 3062.9
H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Cys7-23,cyclic)
Flynn, T.G. et al. (1983) Biochem. Biophys. Res. Commun. 117, 859.
500µg
1mg

SBP0035 - Thr-Ala-Pro-Arg-ANP, human
Urodilatin
MW: 3506.5
H-Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Cys11-27, cyclic)
Gagelmann, M et al. (1988) FEBS Letters 233, 249.
500µg
1mg

Bombesin and Related Peptides

SBP0036 - Bombesin
MW: 1620.1
pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
Anastasi, A. et al. (1971) Experientia 27, 166; Bertaccini, G. et al. (1974) Br. J. Pharmacol. 52, 219 and
227; Brown, M. et al. (1977) Science 196, 998.
5mg
25mg

SBP0037 - [Leu13-ψ(CH2NH)-Leu14]-Bombesin
MW: 1587.9
pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-ψ(CH2NH)-Leu-NH2
Bombesin Receptor Antagonist
Cowan, A. et al. (1988) TIPS 9, 1; Coy, D.H. et al. (1988) J. Biol. Chem. 263, 5056.
500µg
1mg

SBP0038 - [D-Phe6, ß-Ala11, Phe13, Nle14]-Bombesin (6-14)
MW: 1117.4
H-D-Phe-Gln-Trp-Ala-Val-ß-Ala-His-Phe-Nle-NH2
This bombesin analogue has been found to be a high affinity ligand for the human orphan receptor, bombesin receptor subtype 3 (BRS-3). Neither bombesin itself nor any of its analogues that bind to other bombesin receptor subtypes exhibited significant affinity for BRS-3. Binding of this peptide to BRS-3 stimulates the formation of inositol phosphates. Guanosine 5'-(ß,-imido)-triphosphate causes a change in receptor affinity, preventing binding of this ligand. These results indicate that for a member of the bombesin receptor family, BRS-3 has a unique pharmacological profile. The natural ligand for the BRS-3 receptor subtype is presumably either an undiscovered member of the bombesin family or an unrelated peptide.
Mantey, S.A. et al. (1997) J. Biol. Chem. 272, 26062.
1mg
5mg

SBP0039 - [D-Tyr6,ß-Ala11, Phe13,Nle14]-Bombesin (6-14)
MW: 1133.3
H-D-Tyr-Gln-Trp-Ala-Val-ß-Ala-His-Phe-Nle-OH
Tapas K.P. et al. (1998) Eur. J. Pharmacol. 343, 275.
1mg
5mg

SBP0040 - Alytesin
MW: 1535.78
pGlu-Gly-Arg-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
Amphibian bombesin like peptide. In vivo stimulates gastric acid secretion, intestinal contraction, rat uterine contraction and hypertension in the dog. Also modulates thermoregulation following central administration in vivo.
Anastasi, A. et al. (1971) Experientia 27, 166; Bertaccini, G. et al. (1974) Br. J. Pharmacol. 52, 219 and 227; Brown, M. et al. (1977) Science 196, 998.
5mg
25mg

Bradykinin and Related Peptides

SBP0041 - Bradykinin
MW: 1060.3
H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH
Regoli, D. & Barabe, J. (1980) Pharmacol. Rev. 32, 1; Okamoto, H. et al. (1985) Biochem. Biophys. Res. Commun. 112, 701; Barlas, A. (1985) Biochem. Biophys. Res. Commun. 129, 280.
25mg
100mg

SBP0042 - [Des-Arg9,Lys0]-Bradykinin
[Des-Arg10]-Kallidin
MW: 1032.3
H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-OH
10mg
25mg

Brain Natriuretic Peptide (BNP) and Related Peptides

SBP0043 - Brain Natriuretic Peptide, human
BNP-32, human
MW: 3464.6
H-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-OH (Cys10-26, cyclic)
Sudoh, T. et al. (1988) Nature 332, 78; Sudoh, T. et al. (1989) Biochem. Biophys. Res. Commun. 159,
1427.
500µg
1mg

Caerulein and Related Peptides

SBP0044 - Caerulein, non-sulphated
MW: 1271.5
pGlu-Gln-Asp-Tyr-Thr-Gly-Trp-Met-Asp-Phe-NH2
1mg
5mg

SBP0045 - Caerulein, sulphated
MW: 1351.5
pGlu-Gln-Asp-Tyr(SO4H)-Thr-Gly-Trp-Met-Asp-Phe-NH2
Anastasi, A. et al. (1967) Experientia 23, 699.
1mg
5mg

Calcitonin and Related Peptides

SBP0046 - Calcitonin, eel
MW: 3415.4
H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ala-Gly-Thr-Pro-NH2 (Cys1-7, cyclic)
1mg
5mg

SBP0047 - Calcitonin, human
MW: 3418.4
H-Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 (Cys1-7, cyclic)
Nakagawa, Y. et al. (1977) Peptide Chemistry p. 189.
1mg
5mg

SBP0048 - Calcitonin, rat
MW: 3400.4
H-Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Leu-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ser-Ile-Gly-Val-Gly-Ala-Pro-NH2 (Cys1-7, cyclic)
Byfield, P.G.H et al. (1976) FEBS Letters 65, 242.
1mg
5mg

SBP0049 - Calcitonin, salmon
MW: 3432.4
H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 (Cys1-7, cyclic)
Hamilton, C.R. (1974) Am. J. Med. 56, 858
1mg
5mg

Calcitonin Gene Related Peptide (CGRP) and Related Peptides

SBP0050 - CGRP, chicken
MW: 3838.9
H-Ala-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Asp-Phe-Leu-Ser-Arg-Ser-Gly-Gly-Val-Gly-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Cys2-7, cyclic)
Minvielle, S. et al. (1986) FEBS Letters 203, 7.
500µg
1mg

SBP0051 - α-CGRP, human
CGRP-1, human
MW: 3789.9
H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Cys2-7, cyclic)
Morris, H.R. et al. (1984) Nature 308, 746; Le Greves, P. et al. (1985) Eur. J. Pharmacol. 115, 309; Davies, D. et al. (1992) Biochem. Pharm. 43, 1753; Henke, H. et al. (1987) Brain Res. 410, 404.
500µg
1mg

SBP0052 - [Cys(Acm)2&7]-α-CGRP, human
MW: 3934.2
H-Ala-Cys(Acm)-Asp-Thr-Ala-Thr-Cys(Acm)-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2
500µg
1mg

SBP0053 - [Cys(Et)2&7]-α-CGRP, human
MW: 3848
H-Ala-Cys(Et)-Asp-Thr-Ala-Thr-Cys(Et)-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2
This peptide is a potent CGRP-2 receptor agonist. The CGRP alpha analogue exhibits a high potency to inhibit the rat vas deferens twitch response, but induces only a slight inotropic effect in guinea pig atrium even at very high concentrations. It also competes with labelled hCGRP alpha with high affinity for binding sites in rat brain
homogenates. These results suggest that this analogue will be valuable in assessing the functional relevance of
CGRP-2 receptors.
Dumont et al. (1997) Can. J. Physiol.Pharmacol. 75, 671-676.
500µg
1mg

SBP0054 - α-CGRP (8-37), human
MW: 3126.1
H-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2
CGRP receptor antagonist
Chiba, T. et al. (1989) Am. J. Physiol. 256, E331; Hao, H. et al. (1993) Neuropeptides 26, 123.
500µg
1mg

SBP0055 - α-CGRP, rat
MW: 3806.9
H-Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 (Cys2-7, cyclic)
Rosenfeld, M.G. et al. (1983) Nature 304, 129.
500µg 280.00 140.00 140.00
1mg 500.00 250.00 250.00

SBP0056 - [Tyr22]-α-CGRP (22-37), rat
MW: 1786.2
H-Tyr-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2
CGRP fragment suitable for radiolabelling as ligand for immunoassay.
Rosenfeld, M.G. et al. (1983) Nature 304, 129.
1mg
5mg

SBP0057 - CGRP (32-37), rat
MW: 607.7
Val-Gly-Ser-Glu-Ala-Phe-NH2
CCK receptor antagonist
1mg
5mg

Calcium Binding Protein Modulators

Caspase Inhibitors

SBP0058 - Caspase 1 Inhibitor Ac-YVAD aldehyde
MW: 492.5
Ac-Tyr-Val-Ala-Asp-CHO
A specific reversible inhibitor of caspase 1 (ICE, Interleukin 1ß Converting Enzyme)
Thornberry N.A. et al. (1992) Nature 356, 768; Molineaux S.M. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 1809; Walker N.P.C. et al. (1994) Cell 78, 343; Wilson K.P. et al. (1994) Nature 370, 270; Enari M. et al. (1996) Nature 380, 723.
5mg
25mg

SBP0059 - Caspase 3 Inhibitor Ac-DEVD aldehyde
MW: 502.5
Ac-Asp-Glu-Val-Asp-CHO
A potent inhibitor of caspase 3 (Apopain). The peptide aldehyde has been shown to attenuate apoptosis in vitro.
Nicholson D.W. et al. (1995) Nature 376, 37; Enari M. et al. (1996) Nature 380, 723.
5mg
25mg

SBP0060 - Caspase 6 Inhibitor Ac-VEID aldehyde
MW: 500.5
Ac-Val-Glu-Ile-Asp-CHO
A specific inhibitor of caspase 6 (Mch2).
5mg
25mg

SBP0061 - Caspase 8 Inhibitor Ac-IETD aldehyde
MW: 502.5
Ac-Ile-Glu-Thr-Asp-CHO
A caspase 8 inhibitor.
Han Z. et al. (1997) J. Biol. Chem. 272, 13432.
5mg
25mg

Caspase Substrates

SBP0062 - Chromogenic Caspase 4 Substrate Ac-LEVD-pNA
MW: 636.7
Ac-Leu-Glu-Val-Asp-pNA
Chromogenic substrate for caspase 4 (ICH-2)
Talanian R. et al. (1997) J. Biol. Chem. 272, 9677.
5mg
25mg

SBP0063 - Chromogenic Caspase 3 Substrate Ac-DEVD-pNA
MW: 638.6
Ac-Asp-Glu-Val-Asp-pNA
5mg
25mg

SBP0064 - Fluorogenic Caspase 1 Substrate Ac-YEVD-AMC
MW: 723.7
Ac-Tyr-Glu-Val-Asp-AMC
Fluorogenic substrate for caspase 1 (ICE).
Talanian R. et al. (1997) J. Biol. Chem. 272, 9677.
5mg
25mg

SBP0065 - Fluorogenic Caspase 1 Substrate Ac-YVAD-AMC
Interleukin 1ß Converting Enzyme Substrate II
MW: 665.7
Ac-Tyr-Val-Ala-Asp-AMC
Fluorogenic substrate for caspase 1 (ICE).
Thornberry N.A. et al. (1992) Nature 356, 768; Walker N.P.C. et al. (1994) Cell 78, 343.
5mg
25mg

SBP0066 - Caspase 3 Substrate Ac-DEVD-AMC
MW: 675.5
Ac-Asp-Glu-Val-Asp-AMC
A useful fluorogenic caspase-3 substrate
Nicholson, D.W. et al. (1995) Nature 376, 37.
5mg
25mg

SBP0067 - Fluorogenic Caspase 6 Substrate Ac-VEID-AMC
MW: 673.7
Ac-Val-Glu-Ile-Asp-AMC
Fluorogenic substrate for caspase 6 (Mch2)
Takahashi A. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 8395; Martins L.M. et al. (1997) J. Biol.
Chem. 272, 7421; Nagata S. (1997) Cell 88, 355; Talanian R. et al. (1997) J. Biol. Chem. 272, 9677.
5mg
25mg

SBP0068 - Fluorogenic Caspase 3 Substrate Ac-DEVD-AFC
MW: 729.6
Ac-Asp-Glu-Val-Asp-AFC
5mg
25mg

SBP0069 - Fluorogenic Caspase 8 Substrate Ac-IETD-AMC
MW: 675.7
Ac-Ile-Glu-Thr-Asp-AMC
Fluorogenic substrate for caspase 8.
5mg
25mg

Cholecystokinin (CCK) and Related Peptides

SBP0070 - Cholecystokinin (26-33), non-sulphated
CCK Octapeptide (CCK-8), non-sulphated
MW: 1063.3
H-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2
1mg
5mg

SBP0071 - Cholecystokinin (26-33), sulphated
CCK Octapeptide (CCK-8), sulphated
MW: 1143.3
H-Asp-Tyr(SO4H)-Met-Gly-Trp-Met-Asp-Phe-NH2
Ondetti, M.A. et al. (1970) J. Am. Chem. Soc. 92, 195
1mg
5mg

Connexin Peptides

SBP0306 - Gap18
MW: 1834.18
H-Met-Gly-Asp-Trp-Ser-Ala-Leu-Gly-Lys-Leu-Leu-Asp-Lys-Val-Gln-Ala-Cys-OH
Analogue of intracellular amino-terminal tail of connexin 43.
1mg
5mg

SBP0307 - Gap 20
MW: 1114.36
H-Glu-Ile-Lys-Lys-Phe-Lys-Tyr-Gly-Cys-OH
Analogue of intracellular loop of connexin 43.
1mg
5mg

SBP0072 - Gap 26
MW: 1549.81
H-Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg-OH
Analogue of extracellular loop 1 of connexin 43. Gap junction blocker.
1mg
5mg

SBP0073 - Gap 26 Scrambled
MW: 1549.81
H-Pro-Ser-Phe-Asp-Ser-Arg-His-Cys-Ile-Val-Lys-Tyr-Val-OH
Inactive experimental control.
1mg
5mg

SBP0074 - Gap 27 Cx37,43
MW: 1304.56
H-Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile-OH
Analogue of extracellular loop 2 of connexins 37 and 43. Gap junction blocker.
1mg
5mg

SBP0075 - Gap 27 Cx37,43 Scrambled
MW: 1304.56
H-Thr-Phe-Glu-Pro-Ile-Arg-Ile-Ser-Ile-Thr-Lys-OH
Inactive experimental control.
1mg
5mg

SBP0076 - Gap 27 Cx40
MW: 1289.51
H-Ser-Arg-Pro-Thr-Glu-Lys-Asn-Val-Phe-Ile-Val-OH
Analogue of extracellular loop 2 of connexin40. Gap junction blocker.
1mg
5mg

SBP0077 - Gap 27 Cx40 Scrambled
MW: 1289.51
H-Thr-Phe-Glu-Pro-Val-Arg-Val-Ser-Ile-Asn-Lys-OH
Inactive experimental control.
1mg
5mg

Corticotropin Releasing Factor (CRF) and Related Peptides

SBP0078 - Corticotropin Releasing Factor, bovine
MW: 4697.9
H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Asn-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2
Esch, F. et al. (1984) Biochem. Biophys. Res. Commun. 122, 899.
500µg
1mg

SBP0079 - Corticotropin Releasing Factor, human, rat
MW: 4758.1
H-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2
Shibahara, S. et al. (1983) EMBO J. 2, 775.
500µg
1mg

SBP0080 - [Tyr0]-Corticotropin Releasing Factor, human, rat
MW: 4921.3
H-Tyr-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2
500µg
1mg

SBP0081 - Corticotropin Releasing Factor (6-33) Amide, human, rat
MW: 3220.5
H-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-NH2
CRF(6-33) is a CRF fragment, which does not bind to CRF receptors. However, it does bind to CRF-BP (CRF binding protein) and, by displacing biologically active ligands from CRF-BP, it can effectively increase the levels of free CRF and urocortin in the brain.
Sutton, S.W. et al. (1995) Endocrinology 136, 1097; Behan, P. et al. (1995) Nature 378, 284.
500µg
1mg

SBP0082 - [D-Phe12, Nle21&38, C-α-Me-Leu37]-CRF (12-41), human, rat
MW: 3553.6
H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-a-Me-Leu-Nle-Glu-Ile-Ile-NH2
CRF Antagonist
Hernandez, J.-F. et al. (1993) J. Med. Chem. 36, 2860; de Fonseca, F.R. et al. (1996) J. Pharmacol. Exp. Therap. 276, 56.
500µg
1mg

SBP0083 - [D-Phe12, Nle21&38, cyclo-{Glu30-Lys33}]-CRF (12-41), cyclic lactam, human, rat
Astressin
MW: 3563.7
H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 (Glu19-Lys22, cyclic lactam)
Gulyas et al. (1995) PNAS.USA 92, 10575
500µg
1mg

SBP0084 - Corticotropin Releasing Factor, ovine
MW: 4671
H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2
Vale, W. et al. (1981) Science 213, 1394.
500µg
1mg

SBP0085 - α-Helical CRF (9-41)
MW: 3826.9
H-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2
CRF Antagonist
Rivier, J. et al. (1984) Science 224, 889.
500µg
1mg

SBP0086 - α-Helical CRF (12-41)
MW: 3497.6
H-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2
CRF Antagonist
500µg
1mg

SBP0087 - Urocortin, human
MW: 4696.8
H-Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2
Following the discovery of urocortin in rat brain, the human peptide was cloned. Human and rat urocortin show 95% sequence homology. Human urocortin has been shown to bind to CRF-1, CRF-2alpha and CRF-2beta receptors as well as CRF-BP. Urocortin is reported to be more effective at suppressing appetite than CRF, but less potent at producing anxiety-like effects.
Donaldson et al. (1996), Endocrinology 137, 2167; Spina et al. (1996) Science 273, 1561.
500µg
1mg

SBP0088 - Urocortin, rat
MW: 4707.8
H-Asp-Asp-Pro-Pro-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2
Urocortin is a 40 amino acid peptide originally discovered in rat brain. It is a member of the CRF familiy which also includes the frog peptide sauvagine and the fish peptide urotensin. Indeed, urocortin shows a closer sequence homology to urotensin (63%) than to CRF (45%). Urocortin binds more effectively to CRF Type 2 receptors than CRF itself and is probably the endogenous ligand.
Vaughan et al. (1995) Nature 378, 287
500µg
1mg

C-Peptide and Related Peptides

SBP0089 - C-Peptide (1-35), human
Proinsulin (31-65), human
MW: 3617.1
H-Arg-Arg-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH
IMPORTANT - Possible confusion on C-Peptide nomenclature: During the cleavage of proinsulin, the N- and C-terminal dipeptide sequences are clipped from the 35-amino acid sequence, proinsulin (31-65), which connects the insulin A and B chains in proinsulin. The designations "Connecting Peptide" and "C-Peptide" have been used in the past to refer to both the 35-amino acid sequence given above and to the 31 amino acid sequence, C-Peptide (3-33), syn. Proinsulin (33-63), which is the circulating form present in blood. Please ensure that you order only the sequence you require. For C-Peptide (3-33).
Ko, A.S.C. & Smyth, D.G. (1971) Eur. J. Biochem. 20, 190; Oyer, P.E. et al. (1971) J. Biol. Chem. 246, 1375; Frank et al. (1981) Proc. 7th Am. Peptide Symp. p. 729
500µg
1mg

SBP0090 - [Tyr0]-C-Peptide (1-35), human
Tyr-Proinsulin (31-65), human
MW: 3780.3
H-Tyr-Arg-Arg-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH
500µg
1mg

SBP0091 - C-Peptide (3-33), human
Proinsulin (33-63), human
MW: 3020.7
H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH
Recent reports indicate that this peptide may be biologically active and may stimulate insulin secretion. Prolonged administration of C-Peptide to IDDM patients leads to improved renal and autonomic nervous function. IMPORTANT - Possible confusion on C-Peptide nomenclature: During the cleavage of proinsulin, the N- and C-terminal dipeptide sequences are clipped from the 35-amino acid sequence, proinsulin (31-65), which connects the insulin A and B chains in proinsulin. The designations "Connecting Peptide" and "C-Peptide" have been used in the past to refer to both the 31-amino acid sequence given above, which is the circulating form present in blood, and to the 35 amino acid sequence, C-Peptide (1-35), syn. Proinsulin (31-65). Please ensure that you order only the sequence you require. For C-Peptide (1-35).
Ko, A.S.C. & Smyth, D.G. (1971) Eur. J. Biochem. 20, 190; Oyer, P.E. et al. (1971) J. Biol. Chem.
246, 1375; Igano et al. (1981) Bull. Chem. Soc. Japan 54, 3088; Wahren et al. (1996) J. Internal Med.
240, 115.
500µg
1mg

SBP0092 - C-Peptide (3-35), human
Proinsulin (33-65), human
MW: 3305.1
H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH
IMPORTANT - Possible confusion on C-Peptide nomenclature: During the cleavage of proinsulin, the N- and C-terminal dipeptide sequences are clipped from the 35-amino acid sequence, proinsulin (31-65), which connects the insulin A and B chains in proinsulin. The designations "Connecting Peptide" and "C-Peptide" have been used in the past to refer to both the 31-amino acid sequence , which is the circulating form present in blood, and to the 35 amino acid sequence, C-Peptide (1-35), syn. Proinsulin (31-65). Please ensure that you order only the sequence you require.
500µg
1mg

Dynorphin (Neo-Endorphin) and Related Peptides

SBP0093 - Dynorphin A
Prodynorphin (207-223), human; Prodynorphin (209-225), porcine
MW: 2147.8
H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH
Goldstein, A. et al. (1981) Proc. Soc. Natl. Acad. Sci. US 78, 7219; Tachibana, S. et al. (1982) Nature 295, 339; Horikawa, S. et al. (1983) Nature 306, 611.
1mg
5mg

SBP0094 - Dynorphin A (1-13)
MW: 1604.3
H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH
Goldstein, A. et al. (1988) Proc. Soc. Natl. Acad. Sci. USA 76, 6666; Rabkin, S.W. (1992) Regulatory Peptides 41, 95; Kameyama, T. et al. (1994) Neurpharmacology 33, 1167.
1mg
5mg

SBP0095 - [Arg11&13]-Dynorphin A (1-13)-Gly-NH(CH2)5NH2
DAKLI
MW: 1801.5
H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Arg-Leu-Arg-Gly-NH(CH2)5NH2
Dynorphin A analog kappa ligand.
Goldstein, A. et al. (1988) Proc. Soc. Natl. Acad. Sci. USA 85, 7375.
500µg
1mg

SBP0096 - Dynorphin B
Rimorphin
MW: 1571.1
H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH
Fischli, W. et al. (1982) Proc. Soc. Natl. Acad. Sci. USA 79, 5435; Kilpatrick, D. et al. (1982) Life Science 31, 1849; Simpson, J.N. et al. (1992) Neuroscience Letters 137, 149.
500µg
1mg

SBP0097 - Nociceptin
Orphanin FQ
MW: 1809.4
H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln-OH
Meunier, J.-C. et al. (1995) Nature 377, 532; Shimohigashi, Y. et al. (1996) J. Biol. Chem. 271, 23642.
1mg
5mg

SBP0098 - Nociceptin (1-13) Amide
MW: 1381.6
H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-NH2
This nociceptin fragment is reported to be the smallest fragment still retaining full efficacy and potency in the mouse vas deferens and guinea pig ileum bioassays.
Calo, G. et al. (1996) Eur. J. Pharmacol. 311, R3-R5; Guerrini, R. et al. (1997) J. Med. Chem. 40, 1789.; Calo, G. et al. (1997) Can. J. Physiol. Pharmacol. 75, 713.
5mg
25mg

SBP0099 - [Phe1-ψ(CH2-NH)-Gly2]-Nociceptin (1-13) Amide
MW: 1367.6
H-Phe-ψ(CH2-NH)-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-NH2
This peptide is a competitive antagonist of nociceptin.
Guerrini et al. (1998) Br. J. Pharmacol. 123, 163.
500µg
1mg

Endomorphins and Related Peptides

SBP0100 - Endomorphin-1
MW: 610.7
H-Tyr-Pro-Trp-Phe-NH2
Endomorphin-1 is a tetrapeptide peptide isolated from the mammalian brain that exhibits an exceptionally high specificity for the µ-opiate receptor and may well be a natural ligand for this receptor. It induces prolonged and potent analgesia in mice.
Zadina et al. (1997) Nature 386, 499
5mg
25mg

SBP0101 - Endomorphin-2
MW: 571.7
H-Tyr-Pro-Phe-Phe-NH2
Endomorphin-2 is an endogenous analogue of endomorphin-1 and may also be a natural ligand for the µ-opiate receptor.
Zadina et al. (1997) Nature 386, 499
5mg
25mg

Endorphins, Lipotropins, Pro-Opiomelanocortin Fragments and Related Peptides

SBP0102 - ß-Endorphin, human
ß-Lipotropin (61-91), human
MW: 3465.6
H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu-OH
Li, C.H. et al. (1977) J. Med. Chem. 20, 325.
1mg
5mg

SBP0103 - ß-Endorphin, porcine
MW: 3424.8
H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Val-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln-OH
500µg
1mg

Endothelins and Related Peptides

SBP0104 - Big Endothelin-1, human
MW: 4283.6
H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-His-Val-Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Arg-Ser-OH (Cys1-15, Cys3-11, dicyclic)
Itoh et al. (1988) FEBS Letters 231, 440
500µg
1mg

SBP0105 - Endothelin 1, dog, human, porcine, rat
MW: 2492.2
H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH (Cys1-15, Cys3-11, dicyclic)
Itoh, Y. et al. (1988) FEBS Letters 231, 440; Yanagisawa, M. et al. (1988) Nature 332, 411
500µg
1mg

SBP0106 - N-Succinyl-[Glu9, Ala11&15]-Endothelin (8-21)
IRL 1620
MW: 1821.2
Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH
Endothelin ET-B receptor antagonist
Takai et al. (1992) Biochem. Biophys. Res. Commun. 184, 953.
500µg
1mg

SBP0107 - BQ123
MW: 610.8
Cyclo(D-Asp-Pro-D-Val-Leu-D-Trp)
Endothelin antagonist selective for ET-A receptor subtype.
Atkinson, R.A. & Pelton, J.T. (1992) FEBS Letters 296, 1; Eguchi, S. et al. (1992) FEBS Letters 302, 243; Ihara, M. et al. (1992) Life Science 50, 247; Hiley, C.R. et al. (1992) Biochem. Biophys. Res. Commun. 184, 504; Ohlstein, E.H. et al. (1992) Eur. J. Pharmacol. Mol. 225, 347; Webb, M.L. et al. (1992) Biochem. Biophys. Res. Commun. 185, 887.
1mg
5mg

Enkephalin and Related Peptides

SBP0108 - [Leu5]-Enkephalin
Dynorphin A (1-5); a-Neoendorphin (1-5)
MW: 555.7
H-Tyr-Gly-Gly-Phe-Leu-OH
Hughes, J. et al. (1975) Nature 258, 577.
25mg
100mg

SBP0109 - [Leu5]-Enkephalin Amide
MW: 554.7
H-Tyr-Gly-Gly-Phe-Leu-NH2
25mg
100mg

SBP0110 - [Met5]-Enkephalin Amide
MW: 572.8
H-Tyr-Gly-Gly-Phe-Met-NH2
Chang, J.K. et al. (1976) Life Science 18, 1473.
25mg
100mg

SBP0111 - [D-Ala2,Leu5,Arg6]-Enkephalin
Dalargin
MW: 725.9
H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH
Ilylnsky, O.B. et al. (1990) Ann. N.Y. Acad. Sci. 594, 461.
10mg
25mg

Enterostatins

SBP0112 - Enterostatin, human
MW: 496.6
H-Ala-Pro-Gly-Pro-Arg-OH
This pentapeptide is released from the N-terminal of pancreatic colipase. It is reported to act as a systemic satiety factor governing fat intake.
Erlanson-Albertsson C. & Larsson A (1988) Regul. Peptides 22, 325; Erlanson-Albertsson C. & Larsson A (1988) Biochimie 70, 1245; Erlanson-Albertsson C. (1991) Physiol. Behav. 49, 1191.
5mg
25mg

Exendins and Fragments

SBP0113 - Exendin 3
MW: 4203.1
H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Exendin-3 is a 39-mer peptide, originally isolated from the venom of the Guatemalan beaded lizard (Heloderma horridum). The peptide binds to the GLP-1 receptor and acts as a potent GLP-1 (7-36) amide agonist.
Eng et al. (1992) JBC 267, 7402
500µg
1mg

SBP0114 - Exendin 4
MW: 4187.1
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Exendin-4 is a 39-mer peptide, originally isolated from the venom of gila monster (Heloderma suspectum). The peptide binds to the GLP-1 receptor and acts as a potent GLP-1 (7-36) amide agonist. Differs from exendin-3 by only 2 N-terminal amino acid substitutions.
Fehmann et al. (1994) Peptides 15, 453
500µg
1mg

SBP0115 - Exendin 4 (3-39)
MW: 3992.8
H-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Exendin-4 (3-39) is a potent GLP-1 (7-36) amide receptor antagonist.
Montrose-Rafizadch et al. (1996) Regulatory Peptides 64, 131
500µg
1mg

SBP0116 - Exendin 3 (9-39)
MW: 3370.2
H-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Exendin (9-39) binds with high affinity to the glucagon-like peptide-1 (7-36) amide receptor acting as a potent GLP-1 antagonist.
Eng J. et al. (1992) J. Biol. Chem. 267, 7402; Raufman, J.-P. et al. (1992) J. Biol. Chem. 267, 21432; Fehmann, H.C. et al. (1994) Peptides 15, 453.
500µg
1mg

Fibrinogen Fragments and Related Peptides

SBP0117 - Fibrinopeptide A, human
MW: 1536.8
H-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-OH
1mg
5mg

SBP0118 - GPRP Fibrin Antipolymerant
MW: 425.5
H-Gly-Pro-Arg-Pro-OH
Plow E.F. et al. (1987) Biochem. Pharmacol. 36, 4035
This peptide is supplied as the acetate salt.
25mg
100mg

SBP0119 - RGDS (Fibronectin Attachment Peptide)
MW: 433.5
H-Arg-Gly-Asp-Ser-OH
Pierschbacher, M.D. et al. (1984) Nature 309, 30; Gartner, T.K. et al. (1985) J. Biol. Chem. 260, 11891; Ginsberg, M. et al. (1985) J. Biol. Chem. 260, 3931; Haverstick et al. (1985) Blood 66, 946; Thomas D.D. et al. (1985) J. Exp. Med. 162, 1715.
10mg
25mg

SBP0120 - GRGDS (Fibronectin Attachment Peptide)
MW: 490.5
H-Gly-Arg-Gly-Asp-Ser-OH
Akiyama, S.K. & Yamada, K.M. (1985) J. Biol. Chem. 260, 10402; Humphries, M.J. et al. (1986) Science 233, 467
10mg
25mg

SBP0121 - GRGDSPK (Fibronectin Attachment Peptide)
MW: 715.9
H-Gly-Arg-Gly-Asp-Ser-Pro-Lys-OH
Pytela, R. et al. (1986) Science 231, 1559.
1mg
5mg

SBP0122 - Tyr-Amyloid P Component (27-38) Amide
[Tyr0]-Amyloid P Component Dodecapeptide
MW: 1657.1
H-Tyr-Glu-Lys-Pro-Leu-Gln-Asn-Phe-Thr-Leu-Cys-Phe-Arg-NH2
Dhawan, S,. et al. (1990) Biochem. Biophys. Res. Commun. 171, 1284
1mg
5mg

SBP0123 - Tyr-Amyloid P Component (33-38) Amide
[Tyr0]-Amyloid P Component Hexapeptide
MW: 948.2
H-Tyr-Phe-Thr-Leu-Cys-Phe-Arg-NH2
Dhawan, S,. et al. (1990) Biochem. Biophys. Res. Commun. 171, 1284
1mg
5mg

Galanin and Related Peptides

SBP0124 - Galanin, human
MW: 3157.5
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser-OH
Bersani, M. et al. (1991) FEBS Letters 283, 189; Evans, H.F. et al. 81991) Endocrinology 129, 1682, Schmidt W.E. et al. (1991) Proc. Soc. Natl. Acad. Sci. USA 88, 11435.
500µg
1mg

SBP0125 - Galanin, porcine
MW: 3211
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-His-Asp-Lys-Tyr-Gly-Leu-Ala-NH2
Tatemoto, K. et al. (1983) FEBS Letters 164, 124.
500µg
1mg

SBP0126 - Galanin, rat
MW: 3164.3
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-His-Gly-Leu-Thr-NH2
Kaplan, L.M. et al. (1988) Proc. Soc. Natl. Acad. Sci. USA 85, 1065.
500µg
1mg

SBP0127 - Galanin (1-13) - Pro2-(Ala-Leu)2-Ala Amide
M40
MW: 1981.6
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2
Leibowitz, S.F. & Kim. T. (1992) Brain Res. 599, 148; Crawley, J.N. et al. (1993) Brain Res. 600, 268.
500µg
1mg

SBP0128 - Galanin (1-13) - Bradykinin (2-9) Amide
MW: 2233.9
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-NH2
Oegren, O. et al. (1992) Neuroscience 51, 1: Bartfai, T. et al. (1992) TIPS 13, 312.
500µg
1mg

SBP0129 - Galanin (1-13) - Spantide-NH2
C7
MW: 2828.6
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2
Crawley, J.N. et al. (1993) Brain Res. 600, 268.
500µg
1mg

SBP0130 - Galanin (1-13) - Substance P (5-11) Amide
Galantide
MW: 2199.8
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
Bartfai, T. et al. (1991) Proc. Soc. Natl. Acad. Sci. USA 88, 10961; Lindskog, S. et al. (1992) Eur. J. Pharmacol. 210, 183; Langel, U. et al. (1992) Int. J. Peptide Protein Res. 39, 516; Bartfei, T. et al. (1992) TIPS 13, 312.
500µg
1mg

Gastric Inhibitory Polypeptide (GIP) and Related Peptides

SBP0131 - Gastric Inhibitory Polypeptide (GIP), human
MW: 4984.2
H-Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-OH
Moody, A. et al. (1981) FEBS Letters 123, 205
500µg
1mg

Gastrin and Related Peptides

SBP0132 - Gastrin I, human
MW: 2098.5
pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
Bentley, P.H. et al. (1966) Nature 209, 583; Walsh, J.H. et al. (1977) Fed. Proc. 36, 1719.
1mg
5mg

SBP0133 - Gastrin I, rat
MW: 2126.2
pGlu-Arg-Pro-Pro-Met-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
Reeves, J.R. et al. (1981) Peptides 2, 45; Schaffer et al. (1982) Peptides 3, 693.
1mg
5mg

SBP0134 - [Leu15]-Gastrin (5-17)
[Leu11]-Minigastrin
MW: 1628.8
H-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Leu-Asp-Phe-NH2
1mg
5mg

SBP0135 - Pentagastrin
MW: 767.9
Boc-ß-Ala-Trp-Met-Asp-Phe-NH2
25mg
100mg

Gastrin Releasing Peptide (GRP) and Related Peptides

SBP0136 - Gastrin Releasing Peptide (GRP), human
MW: 2859.4
H-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
Spindel, E.R. et al. (1984) Proc. Soc. Natl. Acad. Sci. USA 81, 5699; Sunday, M.E. et al. (1988) Lab. Invest. 54, 5; Olsen, L. et al. (1992) Endocrinology 130, 2710; Steel, J.H. et al. (1992) Endocrinology 130, 2587.
500µg
1mg

Ghrelins and Related Peptides

SBP0137 - Ghrelin, human
MW: 3370.9
H-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Produced mainly in the stomach, it stimulates release of growth hormone fro the pituitary gland in vitro and in vivo, and regulates feeding, growth and energy production.
1mg
5mg

SBP0138 - Ghrelin, rat
MW: 3314.83
H-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Produced mainly in the stomach, it stimulates release of growth hormone fro the pituitary gland in vitro and in vivo, and regulates feeding, growth and energy production.
1mg
5mg

SBP0139 - des-Gln14-Ghrelin, rat
MW: 3186.70
H-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Produced producd by alternative splicing of the rat ghrelin gene. Potently induces Ca2+ release in cells expressing GHS receptors (EC50 = 2.4nM) and stimulates GH release in vivo.
1mg
5mg

SBP0140 - Biotinyl-Ghrelin, human
MW: 3592.9
Biotin-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Labelled with biotin at the N-terminus.
1mg
5mg

SBP0141 - Biotinyl-Ghrelin, rat
MW: 3536.83
Biotin-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Labelled with biotin at the N-terminus.
1mg
5mg

SBP0142 - Biotinyl-des-Gln14-Ghrelin, rat
MW: 3408.70
Biotin-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Labelled with biotin at the N-terminus.
1mg
5mg

SBP0143 - Non-octanoyl-Ghrelin, human
MW: 3244.74
H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Non-acylated control.
1mg
5mg

SBP0144 - Non-octanoyl-Ghrelin, rat
MW: 3188.67
H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Non-acylated control.
1mg
5mg

SBP0145 - Non-Octanoyl-des-Gln14-Ghrelin, rat
MW: 3060.54
H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH
Non-acylated control.
1mg
5mg

SBP0146 - Hexarelin
GHRP6
MW: 886.06
H-His-2Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2
500µg
1mg

Glucagon and Related Peptides

SBP0147 - Glucagon (1-29), bovine, human, porcine
MW: 3482.6
H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
500µg
1mg

SBP0148 - Glucagon (19-29), bovine, human, porcine
MW: 1352.7
H-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
Mallat, A. et al. (1987) Nature 325, 620.
1mg
5mg

SBP0149 - [Des-His1,Des-Phe6,Glu7]-Glucagon (1-29), bovine, human, porcine
MW: 3212.7
H-Ser-Gln-Gly-Thr-Thr-Ser-Glu-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
A glucagon receptor antagonist. It binds to the glucagon receptor, but fails to activate the adenylate cyclase signal transduction system.
Azizeh, B.Y. et al. (1997) J. Med. Chem. 40, 2555
500µg
1mg

Glucagon-Like Peptide (GLP) and Related Peptides

 

SBP0150 - Glucagon-Like Peptide I (7-36) Amide, human
Preproglucagon (78-107) Amide, human
MW: 3297.5
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
Bell, G. et al. 81983) Nature 304, 368.
500µg
1mg

SBP0151 - Glucagon-like Peptide 2, human
GLP-2
MW: 3766.7
H-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH
Primary cleavage product of proglucagon in intestinal L cells. Recent studies indicate that GLP-2 has trophic action on the jejenum, ileum and colon. It , or analogues, should be potential candidates for treating short bowel syndrome.
Orskov C. et al. (1986) Endocrinology 119, 1467; Buhl T. et al. (1988) J. Biol. Chem. 263, 8621; Orskov C. et al. (1989) FEBS Letters 247, 193; Drucker D.J. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 7911; Tsai C.H. et al. (1997) Am. J. Physiol. 272, G662.
500µg
1mg

Growth Factors and Related Peptides

SBP0152 - VEGF Exon 6 Peptide
MW: 1748.4
H-Gly-Lys-Gly-Gln-Lys-Arg-Lys-Arg-Lys-Lys-Ser-Arg-Tyr-Lys-OH
1mg
5mg

Growth Hormone Releasing Factors (GRF, GHRH), and Related Peptides

SBP0153 - Growth Hormone Releasing Factor (1-44), bovine
MW: 5108.6
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2
Esch, F. et al. (1983) Biochem. Biophys. Res. Commun. 17, 772.
500µg
1mg

SBP0154 - Growth Hormone Releasing Factor (1-44), human
MW: 5040.4
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Guillemin, R. et al. (1982) Science 218, 585.
500µg
1mg

SBP0155 - Growth Hormone Releasing Factor (1-29) Amide, human
MW: 3358.4
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Zarandi, M. et al. (1990) Int. J. Peptide Protein Res. 36, 499; Vance, M.L. (1990) Clin. Chem. 36, 415; Zarandi, M. et al. (1992) Int. J. Peptide Protein Res. 39, 211.
500µg
1mg

SBP0156 - [D-Ala2]-GRF (1-29) amide, human
MW: 3358.4
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
In terms of GH secretion from the pituitary, this GHRH analogue is about 50 times more potent than GHRH (1-29) itself.
Lance V.A. et al. (1984) Biochem. Biophys. Res. Commun. 119, 265; Robberecht P. et al. (1986) Peptides 7 (Suppl. 1), 53; Campbell et al. (1991) Peptides 12, 569.
500µg
1mg

SBP0157 - [D-Tle2]-GRF (1-29) amide, human
MW: 3400
H-Tyr-D-Tle-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Lidicky J. et al. (1992) Biopharm 2, 147.
500µg
1mg

SBP0158 - [D-Tle2,Nle26]-GRF (1-29) amide, human
MW: 3382
H-Tyr-D-Tle-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-NH2
500µg
1mg

SBP0159 - [Nle26]-Growth Hormone Releasing Factor (1-29) Amide, human
MW: 3340.4
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-NH2
Rivier, J. et al. (1988) Ann. N.Y. Acad. Sci. 527, 44.
500µg
1mg

SBP0160 - Growth Hormone Releasing Factor (1-44), ovine
MW: 5122.6
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2
Brazeau, P. et al. (1984) Biochem. Biophys. Res. Commun. 125, 606.
500µg
1mg

HPV Peptides

SBP0161 - HPV-16 E7
MW: 1210.4
H-Tyr-Met-Leu-Asp-Leu-Gln-Pro-Glu-Glu-Thr-Thr-OH
Peptide from HPV used in immunoassay.
1mg
5mg

HIV Related Peptides

SBP0162 - HIV Peptide gp120 (254-274)
MW: 2208.9
H-Cys-Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-OH
Ho, D.D. et al. (1988) Science 239, 1021.
500µg
1mg

SBP0163 - HIV Protease Substrate III
MW: 1314.7
H-His-Lys-Ala-Arg-Val-Leu-p-nitro-Phe-Glu-Ala-Nle-Ser-NH2
Pennington, M.W. et al. (1990) Proc. 21st Europ. Peptide Symp. p. 787, eds.: Giralt, E. & Andreu, D.
(Escom, Leiden).
1mg
5mg

Interleukin Fragments and Related Peptides

SBP0164 - Interleukin-6 (88-121), human
MW: 4023.8
H-Ile-Ile-Thr-Gly-Leu-Leu-Glu-Phe-Glu-Val-Tyr-Leu-Glu-Tyr-Leu-Gln-Asn-Arg-Phe-Glu-Ser-Ser-Glu-Glu-Gln-Ala-Arg-Ala-Val-Gln-Met-Ser-Thr-Lys-OH
A competitive inhibitor of IL-6 binding
Ekida, T et al. (1992) Biochem. Biophys. Res. Commun. 188, 912.
500µg
1mg

Ion Channel Modulators

SBP0165 - ß-Pompilidotoxin
MW: 1557.90
H-Arg-Ile-Lys-Ile-Gly-Leu-Phe-Asp-Gln-Leu-Ser-Arg-Leu-NH2
Slows neuronal Na+ channel inactivation.
Konno et al (1998) Biochem.Biophys.Res.Comm. 260 612.
500µg
1mg

SBP0166 - Charybdotoxin
MW: 4295.95
pGlu-Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Gln-Arg-Leu-His-Asn-Thr-Ser-Arg-Gly-Lys-Cys-Met-Asn-Lys-Lys-Cys-Arg-Cys-Tyr-Ser-OH (Cys7-28, Cys13-33, Cys17-35, tricyclic)
Specific inhibitor of the high conductance Ca2+-activated K+ channel..
Miller et al (1995) Nature 313 316.
0.1 mg
500µg

SBP0167 - Iberiotoxin
MW: 4230.00
pGlu-Phe-Thr-Asp-Val-Asp-Cys-Ser-Val-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Lys-Asp-Leu-Phe-Gly-Val-Asp-Arg-Gly-Lys-Cys-Met-Gly-Lys-Lys-Cys-Arg-Cys-Tyr-Gln-OH (Cys7-28, Cys13-33, Cys17-35, tricyclic)
Specific inhibitor of the high conductance Ca2+-activated K+ channel..
Galvez et al (1990) J.Med.Chem 37 636.
0.1 mg
500µg

Leptin Fragments and Related Peptides

SBP0168 - Leptin (22-56), human
MW: 3950.6
H-Val-Pro-Ile-Gln-Lys-Val-Gln-Asp-Arg-Thr-Lys-Thr-Leu-Ile-Lys-Thr-Ile-Val-Thr-Arg-Ile-Asn-Asp-Ile-Ser-His-Thr-Gln-Ser-Val-Ser-Ser-Lys-Gln-Lys-OH
This leptin fragment has been shown to reduce food intake in rats.
Samson W.K. et al. (1996) Endocrinology 137, 5182.
500µg
1mg

Luteinizing Hormone Releasing Hormone (LHRH) and Related Peptides

SBP0169 - LHRH, human
Gonadorelin
MW: 1182.4
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
Rivier, J. & Vale, W.W. (1978) Life Science 23, 869; Tilemans, D. et al. (1992) Endocrinology 130,
887.
10mg
25mg

SBP0170 - [D-Ala6]-LHRH
MW: 1196.5
pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2
Monahan, M.W. et al. (1973) Biochem. 12, 4616.
5mg
25mg

SBP0171 - [D-Lys6]-LHRH
MW: 1253.6
pGlu-His-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-NH2
5mg
25mg

SBP0172 - [D-Trp6]-LHRH
Triptorelin
MW: 1311.6
pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
Schally, A.V. et al. (1985) Proc. Soc. Natl. Acad. Sci. USA 82, 2498.
5mg
25mg

SBP0173 - [D-Ser(tBu)6,Aza-Gly10]-LHRH
Goserelin
MW: 1269
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Aza-Gly-NH2
500µg
1mg

SBP0174 - [D-Tle6,Pro-NHEt9]-LHRH
Lecirelin
MW: 1209.4
pGlu-His-Trp-Ser-Tyr-Tle-Leu-Arg-Pro-NHEt
This position 6 D-tert-leucine substituted LHRH analogue was compared with [D-Ala6, Pro-NHEt9]-LHRH and found to significantly more active in sustaining enhanced LH and FSH in heifers.
Flegel (1983) Peptides 1982, Walter de Gruyter & Co., Berlin, New York, pp 551.
5mg
25mg

SBP0175 - [Des-Gly10,D-Ala6,Pro-NHEt9]-LHRH
MW: 1167.4
pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NHEt
Levitan, D. et al. (1977) Endocrinology 100, 918; Corbin, A. et al. (1978) Infect. Fertil. 23, 81; Coy, D.H. & Schally, A.V. (1978) Ann. Clin. Res. 10, 139.
5mg
25mg

SBP0176 - [Des-Gly10, D-Leu6, Pro-NHEt9]-LHRH
Leuprolide
MW: 1209.5
pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt
Coy, D.H. & Schally, A.V. (1978) Ann. Clin. Res. 10, 139; Dutta, A.S. (1988) Drugs of the Future 13, 43.
5mg
25mg

SBP0177 - [Des-Gly10,Pro-NHEt9]-LHRH
MW: 1153.4
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt
Fujino, M. et al. (1972) Biochem. Biophys. Res. Commun. 49, 863; Okada, J. & Kondo, S. (1985)
Chem. Pharm. Bull. 33, 4464.
5mg
25mg

SBP0178 - [Des-Gly10,D-Trp6,Pro-NHEt9]-LHRH
Deslorelin
MW: 1282.6
pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt
Coy, D.V. & Schally, A.V. (1978) Ann. Clin. Res. 10, 139; Foster, C.M. et al. (1984) J. Clin. Endocrinol. Metab. 59, 801; Klibanski, A. et al. (1989) J. Clin. Endocrinol. Metab. 68, 81.
5mg
25mg

SBP0179 - [Des-Gly10,D-Ser(tBu)6,Pro-NHEt9]-LHRH
Buserelin
MW: 1239.5
p-Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt
500µg
1mg

SBP0180 - [Des-Gly10,D-His2,D-Ser(tBu)6,Pro-NHEt9]-LHRH
[D-His2]-Buserelin
MW: 1239.5
p-Glu-D-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt
Mandatory European Pharmacopoeia reference standard for assay of buserelin
500µg
1mg

SBP0181 - LHRH-III, lamprey
MW: 1259.5
pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2
Selective FSH-releasing activity has been demonstrated on a number of occasions, but until now the molecule responsible for this action has not been isolated. In view of the FSH-releasing action of LHRH, this peptide has often been postulated to be responsible for both FSH and LH secretion from the pituitary. Recent in vitro and in vivo experiments with rats have shown that lamprey LHRH-III selectively stimulates the release of FSH without affecting LH. It is postulated that this sequence may represent the long sought after endogenous FSH-releasing factor.
Sower, S.A. et al. (1993) Endocrinology 132, 1125; Yu, W.H. et al. (1997) Proc. Soc. Natl. Acad. Sci. USA 94, 9499.
5mg
25mg

SBP0182 - LHRH (1-5)-OMe
MW: 716.9
pGlu-His-Trp-Ser-Tyr(Me)-OH
5mg
25mg

Matrix Metalloproteinase (MMP) Substrates

SBP0183 - Matrix Metalloprotease 2 and 9 Substrate DNP-PLGMWSR
MW: 1012.1
DNP-Pro-Leu-Gly-Met-Trp-Ser-Arg-OH
Netzel-Arnett S. et al. (1991) Anal Biochem. 195, 86.
5mg
25mg

Melanocyte Stimulating Hormones (MSH) and Related Peptides

SBP0184 - α-MSH
Acetyl-ACTH (1-13) Amide
MW: 1665.1
Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Harris, J.I. et al. (1957) Nature 179, 1346; Blake, J. & Li. C.H. (1971) Int. J. Protein Res. 111, 185.
5mg
25mg

SBP0185 - [Nle4]-α-MSH
MW: 1647
Ac-Ser-Tyr-Ser-Nle-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
1mg
5mg

SBP0186 - [Nle4,D-Phe7]-α-MSH
MW: 1647
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Sawyer, T. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 77, 5754.
1mg
5mg

SBP0187 - [Des-Acetyl]-α -MSH
ACTH (1-13) Amide
MW: 1623.1
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
1mg
5mg

SBP0188 - [N-Acetyl-Cys4,D-Phe7,Cys10]-α-MSH (4-13), cyclic
MW: 1343.7
Ac-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-NH2 (Cys4-10, cyclic)
Cody, W.L. et al. (1985) J. Med. Chem. 28, 583.
1mg
5mg

SBP0189 - [N-Acetyl-Nle4,Asp5,D-2'-Nal7,Lys10]-α -MSH (4-10) Amide (Asp5-Lys10, cyclic lactam)
SHU-9119
MW: 1074.5
Ac-Nle-Asp-His-D-2`-Nal-Arg-Trp-Lys-NH2 (Asp5-Lys10, cyclic lactam)
Fan et al.(1997) Nature 385, 165 - 168
1mg
5mg

SBP0190 - [N-Acetyl-Nle4,Asp5, D-Phe7,Lys10]-α -MSH (4-10) Amide (Asp5-Lys10, cyclic lactam)
MTII
MW: 1024.3
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2 (Asp5-Lys10, cyclic lactam)
Fan et al.(1997) Nature 385, 165 - 168
1mg
5mg

SBP0191 - [N-Acetyl-Nle4,Gln5,D-Phe7,D-Trp9]-α -MSH (4-10) Amide
HP-228
MW: 984.2
Ac-Nle-Gln-His-D-Phe-Arg-D-Trp-Gly-NH2
Alpha-MSH is known to act as a protective agent against LPS-induced endotoxic shock. HP-228, a structurally related heptapeptide, is a significantly more effective in vivo protective agent. It prevents the induction of nitric oxide synthase activity and endotoxic shock by LPS in rats in vivo, but not in vitro. Thus, its action appears to be indirect, involving a metabolite or additional mediator.
Abou-Mohamed et al. (1995) J. Pharmacol. Exptl. Therap. 275, 584
1mg
5mg

SBP0192 - [Met5,Pro6,D-Phe7,D-Trp9,Phe10]-α -MSH (5-13)
MW: 1206.5
H-Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2
Jayawickreme, C.K. et al. (9954) J. Biol. Chem. 269, 29846.
1mg
5mg

SBP0193 - ß-MSH, human
MW: 2661.3
H-Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH
1mg
5mg

SBP0194 - γ1-MSH
MW: 1512.9
H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2
Nakanishi, S. et al. (1979) Nature 278, 423; Ling, N. et al. (1979) Life Science 25, 1773.
1mg
5mg

SBP0195 - γ2-MSH
MW: 1571.1
H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-OH
Nakanishi, S. et al. (1979) Nature 278, 423; Ling, N. et al. (1979) Life Science 25, 1773.
1mg
5mg

Motilin and Related Peptides

SBP0196 - Motilin, human, porcine
MW: 2699.2
H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-OH
Motilin stimulates gastric motor activity.
De Clercq, P. et al. (1995) Regul. Peptides 55, 79
500µg
1mg

SBP0197 - [Leu13]-Motilin, human, porcine
MW: 2681.2
H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Leu-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-OH
This motilin analogue stimulates gastric motor activity.
Miyashita E. et al. (1988) Biotechnology Letters 10, 763.
500µg
1mg

Myelin Proteins

SBP0198 - Myelin Oligodendrocyte Glycoprotein (1-22)
MOG 1-22
MW: 2458.9
H-Gly-Gln-Phe-Arg-Val-Ile-Gly-Pro-Arg-His-Pro-Ile-Arg-Ala-Leu-Val-Gly-Asp-Glu-Val-Glu-Leu-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0199 - Myelin Oligodendrocyte Glycoprotein (34-56)
MOG 34-56
MW: 2764.2
H-Gly-Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-Asp-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0200 - Myelin Oligodendrocyte Glycoprotein (64-86)
MOG 64-86
MW: 2674.1
H-Glu-Tyr-Arg-Gly-Arg-Thr-Glu-Leu-Leu-Lys-Asp-Ala-Ile-Gly-Glu-Gly-Lys-Val-Thr-Leu-Arg-Ile-Arg-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0201 - Myelin Oligodendrocyte Glycoprotein (74-96)
MOG 74-96
MW: 2536.9
H-Asp-Ala-Ile-Gly-Glu-Gly-Lys-Val-Thr-Leu-Arg-Ile-Arg-Asn-Val-Arg-Phe-Ser-Asp-Glu-Gly-Gly-Phe-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0202 - Proteolipid Protein (41-58)
PLP 41-58
MW: 2228.4
H-Gly-Thr-Glu-Lys-Leu-Ile-Glu-Thr-Tyr-Phe-Ser-Lys-Asn-Tyr-Gln-Asp-Tyr-Glu-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0203 - Proteolipid Protein (184-199)
PLP 184-199
MW: 1593.8
H-Gln-Ser-Ile-Ala-Phe-Pro-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0204 - Proteolipid Protein (190-209)
PLP 190-209
MW: 2029.4
H-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu-Cys-Ala-Asp-Ala-Arg-Met-Tyr-Gly-Val-Leu-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0205 - Myelin Basic Protein (84-102)
MBP 84-102
MW: 2147.5
H-Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro-Pro-Ser-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

SBP0206 - Myelin Basic Protein (143-168)
MBP 143-168
MW: 2636.0
H-Gly-Val-Asp-Ala-Gln-Gly-Thr-Leu-Ser-Lys-Ile-Phe-Lys-Leu-Gly-Gly-Arg-Asp-Ser-Arg-Ser-Gly-Ser-Pro-Met-Ala-OH
Multiple sclerosis candidate autoantigen fragment.
1mg
5mg

Neurokinins, Neuromedins, Other Tachykinins and Related Peptides

SBP0207 - [ß-Ala8]-Neurokinin A (4-10)
MW: 780.9
H-Asp-Ser-Phe-Val-ß-Ala-Leu-Met-NH2
Evangelista, S. et al. (1990) Peptides 11, 293.
1mg
5mg

SBP0208 - Neuromedin U8
MW: 1111.4
H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2
1mg
5mg

Neuropeptide AF and FF, HLWAR77 receptor agonists

SBP0209 - Neuropeptide AF
MW: 1978.19
H-Ala-Gly-Glu-Gly-Leu-Asn-Ser-Gln-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2
Anti-opioid peptide. Agonist or orphan G-coupled receptor HLWAR77.
1 mg
5 mg

SBP0210 - Neuropeptide SF (Neuropeptide FF-amide)
MW: 1367.57
H-Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2
Anti-opioid peptide. Agonist or orphan G-coupled receptor HLWAR77.
1mg
5mg

Neuropeptide Y (NPY) and Related Peptides

 

SBP0211 - Neuropeptide Y, human, rat
MW: 4272.2
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Minth, C. et al. (1984) Proc. Soc. Natl. Acad. Sci. USA 81, 4577; Millar, B.C. et al. (1991) Am. J.
Physiol. 261, H1727.
500µg
1mg

SBP0212 - Biotinyl-Neuropeptide Y, human, rat
MW: 4498.5
Biotinyl-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
500µg
1mg

SBP0213 - [Leu31,Pro34]-Neuropeptide Y, human, rat
MW: 4241.2
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
Fuhlendorf, J. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 87, 182.
500µg
1mg

SBP0214 - [D-Trp32]-Neuropeptide Y, human, rat
MW: 4357.3
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-D-Trp-Arg-Gln-Arg-Tyr-NH2
Balasubramaniam, A. et al. (1994) J. Med. Chem. 37, 811.
500µg
1mg

SBP0215 - Neuropeptide Y (1-24) Amide, human
MW: 2657.2
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-NH2
Martel, J.C. et al. (1990) Mol. Pharmacol. 38, 494.
500µg
1mg

SBP0216 - Neuropeptide Y (2-36), human, rat
MW: 4109
H-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
500µg
1mg

SBP0217 - Neuropeptide Y (3-36), human, rat
MW: 4011.9
H-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Grandt, D. et al. (1996) Regul. Peptides 67, 33.
500µg
1mg

SBP0218 - Neuropeptide Y (13-36), human, rat
MW: 3000.8
H-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
500µg
1mg

SBP0219 - [Leu31,Pro34]-Neuropeptide Y (13-36), human, rat
MW: 2969.8
H-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
500µg
1mg

SBP0220 - Neuropeptide Y, porcine
MW: 4254.2
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Tatemoto, K. et al. (1982) Proc. Soc. Natl. Acad. Sci USA 79, 5485.
500µg
1mg

SBP0221 - Biotinyl-Neuropeptide Y, porcine
MW: 4480.5
Biotinyl-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
500µg
1mg

SBP0222 - [Leu31,Pro34]-Neuropeptide Y, porcine
MW: 4223.2
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
Fuhlendorf, J. et al. (1990) Proc. Soc. Natl. Acad. Sci. 87, 182.
500µg
1mg

SBP0223 - [Pro34]-Neuropeptide Y, porcine
MW: 4223.2
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Pro-Arg-Tyr-NH2
Potter, E.K. et al. (1991) Eur. J. Pharmacol. 193, 15.
500µg
1mg

SBP0224 - [D-Trp32]-Neuropeptide Y, porcine
MW: 4339.3
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-D-Trp-Arg-Gln-Arg-Tyr-NH2
Balasubramaniam, A. et al. (1994) J. Med. Chem. 37, 811.
500µg
1mg

SBP0225 - Neuropeptide Y (2-36), porcine
MW: 4091
H-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Taoudi Benchekroun, M. et al. (1993) Br. J. Pharmacol. 109, 902.
500µg
1mg

SBP0226 - Neuropeptide Y (3-36), porcine
MW: 3993.9
H-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Grandt, D. et al. (1996) Regul. Peptides 40, 161.
500µg
1mg

SBP0227 - Neuropeptide Y (13-36), porcine
MW: 2982.7
H-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Walker, M.W. & Millar, R.J. (1988) Mol. Pharmacol. 34, 779.
500µg
1mg

SBP0228 - [Leu31,Pro34]-Neuropeptide Y (13-36), porcine
MW: 2951.8
H-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
500µg
1mg

SBP0229 - Neuropeptide Y (18-36)
MW: 2457.2
H-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Balasubramanian, A. et al. (1990) J. Biol. Chem. 265, 14724.
500µg
1mg

SBP0230 - Neuropeptide Y (22-36)
MW: 1903.4
H-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Ishiguro, T. et al. (1988) Chem. Pharm. Bull. 36, 2720.
1mg
5mg

SBP0231 - [D-Tyr27&36,D-Thr32]-Neuropeptide Y (27-36)
MW: 1338.7
H-D-Tyr-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Tyr-NH2
When the tyrosine and threonine residues of the C-terminal decapeptide of NPY are replaced by their D-isomers, the peptide acts as an effective antagonist of NPY action on feeding when injected into the paraventricular nucleus (PVN) or ventromedial hypothalamus (VMH) 15 minutes before NPY. It also exhibits anorexic action, reducing the eating pattern of rats deprived of food in a dose-dependent manner.
Myers, R.D. et al. (1995) Brain Res. Bull. 37, 237: Roscoe, A.K. et al. (1995) Peptides 16, 1411.
500µg
1mg

Neurotensin and Related Peptides

SBP0232 - N-Acetyl-Neurotensin (8-13)
MW: 859.1
Ac-Arg-Arg-Pro-Tyr-Ile-Leu-OH
Garnier, L. et al. (1982) Eur. J. Pharmacol. 24, 117.
5mg
25mg

Orexins and Related Peptides


SBP0233 - Orexin A, human
MW: 3562
pGlu-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Cys6-12, Cys7-14, dicyclic)
Orexin A and orexin B are novel hypothalamic neuropeptides discovered by Sakuria et al. (1998) during a search for ligands for orphan G-protein coupled cell surface receptors. These peptides, whose structures are unrelated to any previously known regulatory peptides, are generated by specific proteolytic processing of the single precursor protein prepro-orexin. When administered centrally to rats, these peptides increase prepro-orexin mRNA levels and stimulate food consumption. When food intake was limited, orexin levels increased. They probably play an important role in the physiology of feeding behaviour.
Sakurai, T. et al. (1998) Cell 92, 573.
500µg
1mg

SBP0234 - Orexin B, human
MW: 2899.9
H-Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2
Orexin A and orexin B are novel hypothalamic neuropeptides discovered by Sakuria et al. (1998) during a search for ligands for orphan G-protein coupled cell surface receptors. These peptides, whose structures are unrelated to any previously known regulatory peptides, are generated by specific proteolytic processing of the single precursor protein prepro-orexin. When administered centrally to rats, these peptides increase prepro-orexin mRNA levels and stimulate food consumption. When food intake was limited, orexin levels increased. They probably play an important role in the physiology of feeding behaviour.
Sakurai, T. et al. (1998) Cell 92, 573
500µg
1mg

Oxytocin and Related Peptides

SBP0235 - Oxytocin
MW: 1007.4
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Cys1-6, cyclic)
du Vigneaud, V. et al. (1953) J. Biol. Chem. 205, 949; Thornton, S. et al. 81992) Exp. Physiol. 77, 293.
5mg
25mg

SBP0236 - Carbetocin
(2-O-methyltyrosine)-de-amino-1-carbaoxytocin
MW: 988.1
(CH2)α-CO-Tyr(Me)-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 ((CH2)α -CO1, Cys6, cyclic)
Jost, K (1987) CRC Handbook of Neurohypophyseal Hormone Analogs (eds.: Jost, Lebl & Brtnik; CRC Press Inc.), Vol. II, Part 2, p. 91
5mg
25mg

Pancreatic Polypeptides (PP)

SBP0237 - Pancreatic Polypeptide, human
MW: 4182
H-Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
500µg
1mg

SBP0238 - Pancreatic Polypeptide, rat
MW: 4399.5
H-Ala-Pro-Leu-Glu-Pro-Met-Tyr-Pro-Gly-Asp-Tyr-Ala-Thr-His-Glu-Gln-Arg-Ala-Gln-Tyr-Glu-Thr-Gln-Leu-Arg-Arg-Tyr-Ile-Asn-Thr-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
500µg
1mg

Parathyroid Hormone (PTH) and Related Peptides

SBP0239 - Parathyroid Hormone (1-37), human
MW: 4401.6
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-OH
500µg
1mg

SBP0240 - Parathyroid Hormone (1-34), human
MW: 4118.4
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH
Takai, T. et al. (1979) Peptide Chemistry 1978, 189; Slovik, D. M. et al. (1986) J. Bone & Mineral
Res. 1, 377.
500µg
1mg

SBP0241 - Parathyroid Hormone (1-34), rat
MW: 4059.2
H-Ala-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ala-Ser-Val-Glu-Arg-Met-Gln-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH
Keutmann, H.T. et al. (1985) Endocrinology 117, 1230.
500µg
1mg

Peptide YY (PYY) and Related Peptides

SBP0242 - Peptide YY, human
MW: 4310.4
H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2
Tatemoto, K. et al. (1988) Biochem. Biophys. Res. Commun. 157, 713.
500µg
1mg

SBP0243 - [Leu31,Pro34]-Peptide YY, human
MW: 4293.3
H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2
500µg
1mg

SBP0244 - [Pro34]-Peptide YY, human
MW: 4279.3
H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Pro-Arg-Tyr-NH2
500µg
1mg

SBP0245 - Peptide YY(3-36), human
MW: 4050
H-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2
Eberlein, G.A. et al. (1989) Peptides 10, 797; Grandt, D. et al. (1992) Regul. Peptides 40, 161.
500µg
1mg

SBP0246 - Peptide YY, porcine, rat
MW: 4241.2
H-Tyr-Pro-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Ser-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2
Tatemoto, K. (1982) Proc. Soc. Natl. Acad. Sci. USA 79, 2514.
500µg
1mg

SBP0247 - Peptide YY (13-36), porcine, rat
MW: 3014.7
H-Ser-Pro-Glu-Glu-Leu-Ser-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2
Wahlestedt, C. et al. (1986) Regul. Peptides 13, 307; Walker, M.W. et al. (1988) Mol. Pharmacol. 34, 779.
500µg
1mg

PHI and PHM Peptides

SBP0248 - PHI-27, porcine
MW: 2995.8
H-His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Arg-Leu-Leu-Gly-Gln-Leu-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Ile-NH2
Tatemoto, K. et al. (1981) Proc. Soc. Acad. Sci. USA 78, 6603.
500µg
1mg

SBP0249 - PHI-27, rat
MW: 3011.8
H-His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Tyr-Ser-Arg-Leu-Leu-Gly-Gln-lle-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Ile-NH2
Nishijawa, H. et al. (1985) FEBS Letters 183, 55.
500µg
1mg

Pituitary Adenylate Cyclase Activating Polypeptides (PACAP) and Related Peptides

SBP0250 - PACAP (1-38), human, ovine, rat
MW: 4535
H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2
Miyata, A. et al. (1989) Biochem. Biophys. Res. Commun. 164, 567; Ogi, K. et al. (1990) Biochem.
Biophys. Res. Commun. 173, 1271.
500µg
1mg

SBP0251 - PACAP (1-27) Amide, human, ovine, rat
MW: 3148.1
H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2
Miyata, A. et al. (1989) Biochem. Biophys. Res. Commun. 164, 567
500µg
1mg

SBP0252 - PACAP (6-38), human, ovine, rat
MW: 4025.4
H-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2
Robberecht, P. et al. (1992) Eur. J. Biochem. 207, 239; Robberecht, P. et al. (1992) Molec. Pharmacol. 42, 347.
500µg
1mg

SBP0253 - PACAP (6-27) Amide, human, ovine, rat
MW: 2638.8
H-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2
Robberecht, P. et al. (1991) FEBS Letters 186, 133.
500µg
1mg

Prolactin Releasing Peptides (PrRP) and Related Peptides

SBP0254 - Prolactin Releasing Peptide-31 (PrRP-31), bovine
MW: 3576.5
H-Ser-Arg-Ala-His-Gln-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2
PrRP-31 and PrRP-20 are the first reported hypothalamic peptides that exclusively stimulate the release of prolactin from the pituitary without affecting that of other known hypophyseal hormones. Interestingly, the discovery of these peptides is an example of an orphan peptide receptor being used to identify its own ligand. Working backwards from the human orphan receptor, hGR3, Hinuma et al. (1998) identified a peptide ligand in bovine hypothalamic extracts. After isolation of the respective cDNA in bovine brain, they were able to identify the 31-amino acid peptide (PrRP-31) and 20-amino acid fragment (PrRP-20) corresponding to this sequence. The peptide sequences are reported to be highly conserved in other species (human, rat). PrRP-31 has been shown to stimulate prolactin release from a rat pituitary RC-4B/C adenoma cells, from anterior pituitary cells from lactating rats, and from rat pituitary cells in a perfusion assay.
Hinuma, S. et al. (1998) Nature 393, 272.
500µg
1mg

SBP0255 - Prolactin Releasing Peptide-31 (24-31), bovine; PrRP-31 (24-31), bovine
MW: 1347.8
H-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2
C-Terminal fragment of bovine prolactin-releasing peptide suitable for iodination.
1mg
5mg

SBP0256 - Prolactin Releasing Peptide-20 (PrRP-20), bovine
MW: 2242.8
H-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2
PrRP-20 is believed to be a naturally occurring truncated form of PrRP-31 corresponding to the C-terminal 20 amino
acids of that peptide.
Hinuma, S. et al. (1998) Nature 393, 272.
500µg
1mg

Protease Inhibitors

SBP0257 -Eglin c (60-63) Methyl Ester
MW: 445.5
H-Thr-Asn-Val-Val-OMe
Tsuboi, S. et al. (1979) Chem. Pharm. Bull. 39, 184.
5mg
25mg

Protease Substrates

SBP0258 - Urokinase substrate, Z-γ-Glu(tBu)-Gly-Arg-pNA
MW: 670.7
Z-γ -Glu(tBu)-Gly-Arg-pNA
A substrate for urokinase
Harvey, S.R. et al. (1988) Clin. Exptl. Metastasis 6, 431.
This peptide is supplied as the acetate salt.
5mg
25mg

SBP0259 - Mca-Pro-Leu-Gly-Leu-Dpr(Dnp)-Ala-Arg-NH2
MW: 1093.2
Mca-Pro-Leu-Gly-Leu-Dpr(Dnp)-Ala-Arg-NH2
Knight, C.G. et al. (1992) FEBS Letters 296, 263; Galis, Z.S. et al. (1995) FASEB J. 9, 974.
1mg
5mg

SBP0260 - Suc-Ala-Ala-Pro-Phe-pNA
MW: 640.6
Suc-Ala-Ala-Pro-Phe-pNA
DelMar, E.G. et al. (1979) Anal. Biochem. 99, 316; Nakajima, K. et al. (1979) J. Biol. Chem. 254, 4027.
50mg
250mg

Protein Kinase Related Peptides

SBP0261 - Casein Kinase II Receptor Peptide
MW: 1206.3
H-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu-OH
Klarlund, J.K. & Czech, M.P. (1988) J. Biol. Chem. 263, 15872.
1mg
5mg

SBP0262 - cGMP-Dependent Protein Kinase Substrate
MW: 1575
H-Arg-Lys-Ile-Ser-Ala-Ser-Glu-Phe-Asp-Arg-Pro-Leu-Arg-OH
1mg
5mg

SBP0263 - MAP Kinase Phosphorylation Substrate
EGF Receptor (661-681)
MW: 2318.8
H-Lys-Arg-Glu-Leu-Val-Glu-Pro-Leu-Thr-Pro-Ser-Gly-Glu-Ala-Pro-Asn-Gln-Ala-Leu-Leu-Arg-OH
1mg
5mg

SBP0264 - Protein Kinase C (19-31)
MW: 1544
H-Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val-OH
House, C. & Kemp, B.E. (1987) Science 238, 1726. Alexander, D.R. et al. (1989) Biochem. J. 260, 893.
1mg
5mg

SBP0265 - Protein Kinase C Substrate KRTLRR
MW: 829.1
H-Lys-Arg-Thr-Leu-Arg-Arg-OH
Heasley, L. & Johnson, G.L. (1989) J. Biol. Chem. 264, 8646.
5mg
10mg

SBP0266 - AMP-activated kinase substrate, SAMS
MW: 1779.15
H-His-Met-Arg-Ser-Ala-Met-Ser-Gly-Leu-His-Leu-Val-Lys-Arg-Arg-OH
Phosphorylated by AMPK. Used as an assay for AMPK.
Carling Et al (1989) Eur.J.Biochem. 186 129.
500µg
1mg

SBP0267 - Death-Associated Protein Kinase (DAPK) Substrate
MW: 1578.82
H-Lys-Lys-Arg-Pro-Gln-Arg-Arg-Tyr-Ser-Asn-Val-Phe-OH
Synthetic peptide substrate for death associated protein kinase.
Velentza et al (2001) J.Biol.Chem. 276 38956.
1mg
5mg

SBP0268 - Myosin Light Chain Kinase Inhibitor Peptide
MW: 1444.79
H-Lys-Arg-Arg-Trp-Lys-Lys-Asn-Phe-Ile-Ala-Val-NH2
Competitive myosin light chain kinase inhibitor, (Ki = 1-2.2µM). Also binds calmodulin.
Kemp et al (1987) J.Biol.Chem. 262 2542.
1mg
5mg

SBP0269 - Myosin Light Chain Kinase Inhibitor Peptide 18
MW: 1324.64
H-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-NH2
Selective competitive inhibitor of myosin light chain kinase (IC50=50nm). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA.
Lukas et al (1999) J.Med.Chem. 42 910.
1mg
5mg

SBP0270 - CaM kinase II Inhibitor Peptide
MW: 3374.08
H-Met-His-Arg-Gln-Glu-Thr-Val-Asp-Cys-Leu-Lys-Lys-Phe-Asn-Ala-Arg-Arg-Lys-Leu-Lys-Gly-Ala-Ile-Leu-Thr-Thr-Met-Leu-Ala-OH
Inhibitor of Ca2+-indipendant form of CaM kinase II found in post synaptic densities (IC50=3.6µM).
Rich et al (1989) J.Neurochem. 53 807.
1mg
5mg

SBP0271 - SH2 Binding Domain Inhibitor Ac-Tyr(PO4)-Glu-Glu-Ile-Glu-OH
MW: 803.71
Ac-Tyr(PO4)-Glu-Glu-Ile-Glu-OH
Binds SH2 domain (IC50=1.35µM). Additionally blocks binding of SH2 domain constructs to platelet derived growth factor kinase.
Shahripour et al (1996) Bioorg.Med.Chem.Lett 6 1209.
1mg
5mg

Sauvagine and Related Peptides

SBP0272 - Sauvagine
MW: 4599.9
pGlu-Gly-Pro-Pro-Ile-Ser-Ile-Asp-Leu-Ser-Leu-Glu-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2
Sauvagine is a biologically active peptide isolated from the skin of the tropical frog Phyllomedusa sauvagei. It possesses a number of pharmacological and endocrinological actions, affecting diuresis and the cardiovascular system.
Montecucchi & Henschen (1981) Int. J. Peptide Protein. Res. 18, 113; Vale et al. (1981) Science 213, 1394.
500µg
1mg

SBP0273 - [Tyr0]-Sauvagine
MW: 4781.1
H-Tyr-Glu-Gly-Pro-Pro-Ile-Ser-Ile-Asp-Leu-Ser-Leu-Glu-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2
500µg
1mg

SBP0274 - Anti-Sauvagine 30
MW: 3651.3
H-D-Phe-His-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-The-Ile-OH
This peptide, which is a conformationally constrained analogue of sauvagine, is a selective ligand for CRF type 2ß receptors and has been shown to suppress agonist-induced adenylate cyclase activity in HEK cells expressing murine CRF type 2ß receptors.
Rühmann, A et al. (1998) Proc. Natl. Acad. Sci. USA 95, 15264
500µg
1mg

Secretins

SBP0275 - Secretin, human
MW: 3039.8
H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2
Carlquist, M. et al. (1985) IRC Med. Science 13, 217; Ohta, M. et al. (1992) Biochem. Biophys. Res. Commun. 183, 390.
1mg
5mg

SBP0276 - Secretin, porcine
MW: 3055.9
H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2
Bodansky, M. et al. (1967) J. Amer. Chem. Soc. 89, 6753.
1mg
5mg

Somatostatin and Related Peptides

SBP0277 - Somatostatin 28 (cyclic)
MW: 3149
H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys17-28, cyclic)
Pradayrol, L. et al. (1980) FEBS Letters, 109, 55; Schally, A.V. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 77, 4489.
500µg
1mg

SBP0278 - [Tyr0]-Somatostatin 28 (cyclic)
MW: 3312.2
H-Tyr-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys18-29, cyclic)
500µg
1mg

SBP0279 - Somatostatin (cyclic)
MW: 1638.1
H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys3-14, cyclic)
Brazeau, P. et al. (1973) Science 179, 77; Reubi, J.C. et al. (1982) Endocrinology 110, 1049; Gustaffson, S. et al. (1978) Biochem. Biophys. Res. Commun. 82, 1229; White, R.E. et al. (1991) Nature 351, 570.
5mg
25mg

SBP0280 - [Tyr0]-Somatostatin (cyclic)
MW: 1801.4
H-Tyr-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys4-15, cyclic)
500µg
1mg

Substance P and Related Peptides

SBP0281 - Substance P
MW: 1347.8
H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
Chang, M.M. et al. (1971) Nature 232, 86; Pernow, B. (1983) Pharmacol. Rev. 35, 85; Roberts, A.I. et al. (1982) Cell Immunol. 141, 457.
5mg
25mg

Substance P Antagonists

SBP0282 - [D-Arg1, D-Phe5, D-Trp7&9, Leu11]-Substance P
MW: 1517
H-D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2
Tsau, K. et al. (1985) Eur. J. Pharmacol. 110, 155; Heinz-Erian, P. et al. (1986) Gastroenterology 90, 1455; Fabregat, I. & Razengurt, E.T. (1990) J. Cell Physiol. 145, 88.
1mg
5mg

SBP0283 - [D-Arg1,D-Trp7&9,Leu11]-Substance P
Spantide I
MW: 1496.8
H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2
Folkers, K. et al. (1984) Br. J. Pharmacol. 83, 449; Hakanson, R. et al. (1990) Regul. Peptides 31, 75.
1mg
5mg

Thymopoietin (TP) Fragments

 

SBP0284 - Thymopentin
MW: 679.8
H-Arg-Lys-Asp-Val-Tyr-OH
1mg
5mg

Thymosin and Fragments

 

SBP0285 - Thymosin-α1
MW: 3108.7
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Sztein, M.B. & Goldstein, A.L. (1986) Springer Semin. Immunopathol. 9, 1.
500µg
1mg

SBP0286 - [Ac-Tyr0]-Thymosin-α1
MW: 3271.9
Ac-Tyr-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
500µg
1mg

Urotensins

SBP0287 - Urotensin II, human
MW: 1387.2
H-Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val-OH (Cys5-10, cyclic)
Urotensin II is located in human vascular and cardiac tissue. It is the most potent vasoconstrictor known at the present time (1999), being an order of magnitude more potent than endothelin-1. Immunoreactivity has also been observed in CNS and endocrine tissues. A human orphan receptor for urotensin II has been described.
Coulouarn Y. et al. (1998) Proc. Soc. Acad. Sci. USA 95, 15803; Ames R.S. et al. (1999) Nature 401, 282.
1mg
5mg

SBP0288 - Urotensin II, teleost fish
MW: 1361.8
H-Ala-Gly-Thr-Ala-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val-OH (Cys6-11, cyclic)
Urotensin II is a vasoactive peptide with some homology to somatostatin. It was originally found in the caudal neurosecretory system of the teleost fish, Gillichthys mirabilis.
Pearson, D. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 77, 5021
1mg
5mg

Vasoactive Intestinal Peptide (VIP) and Related Peptides

SBP0289 - Vasoactive Intestinal Peptide, human, porcine, rat
MW: 3326.2
H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Bodanszky, M. et al. (1974) J. Amer. Chem. Soc. 96, 4973; Said, S. I. et al. (1970) Science 169, 1217; Segura, J.J. et al. (1992) Regul. Peptides 37, 145.
500µg
1mg

SBP0290 - [D-Phe2]-Vasoactive Intestinal Peptide, human, porcine, rat
MW: 3386.3
H-His-D-Phe-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Robberecht, P. et al. (1986) Eur. J. Biochem. 159, 45.
500µg
1mg

SBP0291 - [p-chloro-D-Phe6,Leu17]-VIP, human, porcine, rat
MW: 3342.2
H-His-Ser-Asp-Ala-Val-p-Cl-D-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Leu-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
VIP Antagonist
Pandol, S.J. et al. (1986) Am. J. Physiol. 250, G553.
500µg
1mg

SBP0292 - Vasoactive Intestinal Peptide (6-28), human, porcine, rat
MW: 2816.6
H-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Fishbein, V.A. et al. (1994) Peptides 15, 95.
500µg
1mg

SBP0293 - Lys-Pro-Arg-Arg-Pro-Tyr-VIP (7-28), human, porcine, rat
MW: 3467.4
H-Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
VIP Antagonist
Gozes, I. et al. (1989) Endocrinology 125, 2945.
500µg
1mg

SBP0294 - Vasoactive Intestinal Peptide (10-28), human, porcine, rat
MW: 2339.1
H-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Turner, J.T. et al. (1986) Peptides 7, 849; Cox, H.M. & Cuthbert. A.W. (1989) Regul. Peptides 26, 127.
1mg
5mg

SBP0295 - [pGlu16]-Vasoactive Intestinal Peptide (16-28), human, porcine, rat
MW: 1504
pGlu-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Bodanszky, M. et al. (1979) Bioorg. Chem. 8, 399.
1mg
5mg

Vasopressin, Vasotocin and Related Peptides

SBP0296 - [Arg8]-Vasopressin
AVP
MW: 1084.4
H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Cys1-6, cyclic)
Bell, J. et al. (1992) Int. J. Immunopharm. 14, 92.
5mg
25mg

SBP0297 - [Lys8]-Vasopressin
MW: 1056.4
H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Cys1-6, cyclic)
Zaoral, M. et al. (1967) Coll. Czech Chem. Commun. 32, 1242.
5mg
25mg

SBP0298 - [Phe2,Lys8]-Vasopressin
Felypressin
MW: 1040.4
H-Cys-Phe-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Cys1-6, cyclic)
5mg
25mg

SBP0299 - [Phenylacetyl1,O-D-Tyr(Et)2,Val4,Lys6,Arg8,Tyr9]-Vasopressin
MW: 1231.5
Phaa-D-Tyr(Et)-Phe-Val-Asn-Lys-Pro-Arg-Tyr-NH2
1mg
5mg

SBP0300 - [d(CH2)51, D-Ile2,Ile4,Arg8,Ala9]-Vasopressin
MW: 1086.4
Pmp-D-Ile-Phe-Ile-Asn-Cys-Pro-Arg-Ala-NH2 (Pmp1-Cys6, cyclic)
Manning, M. & Sawyer, W.H. (1989) J. Lab. Clin. Med. 114, 617.
1mg
5mg

SBP0301 - [d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr9]-Vasotocin
MW: 1154.5
Pmp-Tyr(Me)-Ile-Thr-Asn-Cys-Pro-Orn-Tyr-NH2 (Pmp1-Cys6, cyclic)
Elands, J. et al. (1987) Eur. J. Pharmacol. 147, 197.
1mg
5mg

SBP0302 - [d(CH2)51,D-Tyr(Et)2,Arg3&8,Val4]-Vasopressin
[d(CH2)51,D-Tyr(Et)2,Arg3,Val4]-AVP
MW: 1145.4
Pmp-Tyr(Et)-Arg-Val-Asn-Cys-Pro-Arg-Gly-NH2
Arginine-vasopressin (AVP) has both vasoconstricting and vasodilating actions. This hypotensive AVP analogue exhibits selective vasodepressor activity that is mediated by neither V1a, V2 or oxytocin receptors nor by NO. This analogue represents one of a new class of pharmacological tools that can be used for investigating the complex cardiovascular actions of AVP and may form the basis for the development of novel antihypertensive agents.
Chan, W.Y. et al. (1998) Br. J. Pharmacol. 125, 803.
5mg
25mg

SBP0303 - [d(CH2)51, Tyr(Me)2, Arg8]-Vasopressin
Manning Compound
MW: 1151.4
Pmp-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Pmp1-Cys6, cyclic)
Kruszynski, M. et al. (1980) J. Med. Chem. 23, 364.
1mg
5mg

SBP0304 - [Arg8]-Vasotocin
MW: 1050.4
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Cys1-6, cyclic)
Acher, R. et al. (1960) Biochim. Biophys. Acta 42, 379.
5mg
25mg

SBP0305 - [Lys8]-Vasotocin
LVT
MW: 1022.3
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Cys1-6, cyclic)
5mg
25mg